Immix Biopharma, Inc. SEC filings IMMX
Immix Biopharma, Inc. has 244 filings in SEC EDGAR's recent list, going back to Jul 20, 2021. Its latest annual report, Form ARS, was filed on Apr 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 6, 2026 | — |
| DEF 14A | Proxy statement | Apr 6, 2026 | Apr 6, 2026 |
| DEFA14A | Additional proxy material | May 19, 2025 | — |
| DEFA14A | Additional proxy material | May 5, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Apr 29, 2025 |
| DEFA14A | Additional proxy material | May 21, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Apr 29, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2023 | — |
| DEF 14A | Proxy statement | Apr 25, 2023 | Apr 25, 2023 |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Apr 25, 2022 |
Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMMX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1873835
- Former names
- Immix Biopharma, Inc. (until Oct 27, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.